Member Info for Dr_Horrible

In medicine terms the difference between hypercholesterolemia and dyslipidemia is that hypercholesterolemia is an excess of cholesterol in the blood while dyslipidemia is an inbalance of lipids (especially cholesterol) in the blood.

It's potentially a long way off, as it needs to go through drug approval process. Not suggesting a huge amount of time as they already have a lot of quality trial evidence, but could be a couple of years or so. But WTFDIK.

https://www.databridgemarketresearch.com/reports/global-dyslipidemia-market

Related to FF as a drug, as it is specifically targeting dyslipidemia in the 2nd one. Then the timing of when its raised and approved by ethics committee would also support that.

It’s where all the best and freshest Fruitflow comes from.

Interesting that this Cardio Fortis video was posted 2 months ago and has over 18,000 views. Must be some good marketing going on.

https://www.youtube.com/watch?v=tvy1kHBT4uA

No bad.

snippet.
https://nature-sciences-sante.eu

We don't know that their shortage of stock has anything to do with FF. There are 7 ingredients in a capsule. It could be any number of issues. Maybe they forgot to oder a new batch of labels.

Nonsense.

There is little chance of dividends until major orders are coming in regular. There needs to be a good wad of cash in the bank first.

They would probably use some money to fund additional studies or buy other companies or technologies. I would hope some kind of media campaign too.

It may not be in any products yet, but should be available B2B via the BH distributor agreement. So Taiwanese and Australian companies can purchase it from BH now I would assume.

Would BH be making any orders now? They are now a distributor for Taiwan, HK, Australia etc. Those places are not subject to the Chinese regs.

That’s my thought, we will likely at least break even this financial year. Then even without BH or additional launches, it should good profit next financial, which has 1/4 of DSM step down number 2.

BH have been multiple of annual sales for ages. But since that started to be reported BH have picked up distribution too. They have a large number of multi-National companies that have shown a strong interest or agreed to commercialise FF.

Then we have Bangladesh’s top Pharma company (Square Pharmaceuticals) working on FF.

Then the whole gut health thing.

Then developing it as a drug.

Even with the most pessimistic glasses on, it’s going to be mega. You can see a very easy path to £20m profit and beyond.

Or is it about £5.5m current sales?

If we have £1m of stock that will sell for about £8m? Current FF annual sales are approx £6m - £8m.

BH orders will be multiple of current FF sales. It will be significant and transformational. The prospective pipeline is significant multiples of existing sales.

What profit/loss do people think there will be this year, and then the next 2 years?

Any supply issue is unlikely to be as a result of PXS, given that they have stock sitting around and can get it out of the door immediately.

If a pharma company is currently doing trials, then I would assume they have some kind of agreement with PXS, but we have not been told anything about that. Would be nice to know more about it.

I meant ‘it seems like a good pharma company Gix’

I would imagine that the whole pricing has changed or will soon. Some cost reduction will be passed on to customers.

Sounds like a pharma company Gix.